Analysts' ratings for Treace Medical Concepts (NASDAQ:TMCI) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 4 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.17, a high estimate of $16.00, and a low estimate of $5.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 48.39%.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Treace Medical Concepts is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Danielle Antalffy | UBS | Lowers | Neutral | $6.50 | $16.00 |
| Drew Ranieri | Morgan Stanley | Lowers | Equal-Weight | $5.50 | $15.00 |
| Danielle Antalffy | UBS | Lowers | Buy | $16.00 | $17.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $7.00 | $17.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $8.00 | $15.00 |
| Rick Wise | Stifel | Lowers | Hold | $6.00 | $15.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Treace Medical Concepts. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Treace Medical Concepts compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
For valuable insights into Treace Medical Concepts's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Treace Medical Concepts analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Treace Medical Concepts
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
A Deep Dive into Treace Medical Concepts's Financials
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Treace Medical Concepts displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 21.12%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -36.54%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Treace Medical Concepts's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.13%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Treace Medical Concepts's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Treace Medical Concepts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.55.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.